Table 4.
Flow mediated dilatation parameters.
| Measure | Pre-Placebo | Post-Placebo | Pre-NO3− | Post-NO3− | Time × Condition (p-Value) |
|---|---|---|---|---|---|
| Baseline SFA diameter (mm) | 6.93 (6.61–7.24) |
7.02 (6.57–7.46) |
6.95 (6.66–7.24) |
7.09 (6.82–7.36) |
0.783 |
| RH peak flow (mL·min−1) | 1093 (968–1218) |
1140 (1005–1275) |
1160 (1040–1279) |
1142 (972–1314) |
0.361 |
| RH AUC (mL) | 367 (306–428) |
417 (363–470) |
395 (352–437) |
409 (342–477) |
0.396 |
| Time to peak dilation (s) | 144 (121–168) |
130 (109–150) |
124 (108–150) |
140 (126–155) |
0.086 |
| Response shear (AUC) | 9997 (8014–11980) |
10904 (8870–12938) |
9038 (7787–10288) |
9199 (7545–10854) |
0.406 |
| Absolute FMD (mm) | 0.30 (0.26–0.35) |
0.29 (0.24–0.32) |
0.28 (0.24–0.32) |
0.37 * (0.31–0.42) |
0.002 |
| FMD·SRAUC−1 (103·s−1) | 5.31 (3.47–7.16) |
4.24 (2.60–5.90) |
4.99 (3.22–6.76) |
6.40 * (4.39–8.41) |
<0.001 |
| Allometric scaled FMD (%) | 4.07 (3.38–4.76) |
3.91 (3.22–4.61) |
3.76 (3.07–4.46) |
4.75 * (4.06–5.45) |
0.010 # |
All data are mean (95% confidence interval). p-values refer to the significance of the F-statistic in two-way (time × condition) repeated measures ANOVA, except allometric scaled FMD, where the p-value (#) refers to the significance in the linear mixed model (LMM) analysis. Allometric scaled FMD was logarithmically transformed to account for variance in base diameter during linear mixed model analysis and the values in the table have been back-logged for clarity. SFA, superficial femoral artery; RH, reactive hyperaemia; AUC, area under the curve; FMD, flow mediated dilatation; SR, shear rate. * Post- NO3− is significantly different from pre-NO3− and the placebo conditions.